An update from Ligand Pharma ( (LGND) ) is now available.
On February 24, 2025, Ligand Pharmaceuticals entered into a $75 million Purchase and Sale Agreement with Castle Creek Biosciences and co-investors to support the Phase 3 clinical study of D-Fi, a gene therapy candidate for dystrophic epidermolysis bullosa (DEB). Ligand invested $50 million, receiving a high single-digit royalty on worldwide sales of D-Fi and warrants to purchase shares of Castle Creek. This collaboration aims to advance an orphan drug-designated therapy for a serious unmet medical need, reflecting Ligand’s commitment to investing in groundbreaking treatments and expanding its portfolio of revenue-generating assets.
More about Ligand Pharma
Ligand Pharmaceuticals is a biopharmaceutical company focused on enabling scientific advancement by supporting the clinical development of high-value medicines. The company generates value for stockholders by creating a diversified portfolio of biopharmaceutical product revenue streams and focuses on funding mid- to late-stage drug development programs in return for economic rights. Ligand partners with other pharmaceutical companies to leverage their expertise in late-stage development, regulatory management, and commercialization.
YTD Price Performance: 7.98%
Average Trading Volume: 104,713
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.21B
For a thorough assessment of LGND stock, go to TipRanks’ Stock Analysis page.